MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$5,756K
EPS
-$0.78
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-09-30
2025-06-30
2024-12-31
Research and development
1,545
6,914
9,583
17,872*
General and administrative
5,208
4,801
5,016
6,275*
Restructuring and impairment charges
612
0
0
368*
Total operating expenses
7,365
11,715
14,599
24,514
Loss from operations
-7,365
-11,715
-14,599
-24,514*
Interest income
609
1,026
1,197
2,116*
Gain on sale of nonfinancial asset
1,000
-
-
-
Other expenses
-
538
-
-
Interest expense
0
-
302
398*
Net loss
-5,756
-11,227
-13,704
-22,797
Basic EPS
-0.78
-1.53
-1.87
-3.13
Diluted EPS
-0.78
-1.53
-1.87
-3.13
Basic Average Shares
7,343,909
7,323,106
7,311,032
7,284,268
Diluted Average Shares
7,343,909
7,323,106
7,311,032
7,284,268
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$5,756K
Gain on sale of
nonfinancial asset
$1,000K
Interest income
$609K
Loss from operations
-$7,365K
Total operating
expenses
$7,365K
General and
administrative
$5,208K
Research and development
$1,545K
Restructuring and impairment
charges
$612K
Buy us a coffee
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)